Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$4.49 USD
+0.23 (5.28%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $4.48 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Voyager Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VYGR 4.49 +0.23(5.28%)
Will VYGR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Other News for VYGR
VYGR forms Shooting Star Candlestick on September 17
VYGR's price rises by 0.95% on September 16, though its technical setup remains stable.
Is VYGR poised for gains? 200 Day Moving Average Support shows up after rising 0.72%
VYGR Makes Notable Cross Below Critical Moving Average
Voyager Therapeutics (VYGR): HC Wainwright & Co. Reiterates Buy Rating | VYGR Stock News